Filtered By:
Source: Heart Rhythm

This page shows you your search results in order of date. This is page number 9.

Order by Relevance | Date

Total 406 results found since Jan 2013.

Liver cirrhosis is independently associated with increased in-hospital mortality in patients undergoing left atrial appendage occlusion device implantation
This study aimed to assess procedural outcomes in patients with cirrhosis who underwent LAAO with a Watchman device by using a contemporary administrative claims database.
Source: Heart Rhythm - April 28, 2022 Category: Cardiology Authors: Sahith Reddy Thotamgari, Aakash R. Sheth, Harsh P. Patel, John Bretzman, Robert C. Ward, Samarthkumar Thakkar, Jaimin T. Patel, Samuel J. Asirvatham, David R. Holmes, Alexander Egbe, Abhishek Deshmukh, Christopher V. DeSimone Tags: Research Letter Source Type: research

Adverse events associated with the AtriClip device for left atrial appendage occlusion: A Food and Drug Administration MAUDE database study
Based on autopsy studies, the left atrial appendage has been implicated as the cause of stroke in>90% of cases with nonvalvular atrial fibrillation. The AtriClip device (Atricure, West Chester, OH) is used for left atrial appendage exclusion at the time of median sternotomy or thoracoscopically (as a  stand-alone procedure or at the time of hybrid epicardial-endocardial ablation for atrial fibrillation).1–3 The real-world safety profile of AtriClip has not been evaluated, and we analyzed adverse events related to its use reported to the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database.
Source: Heart Rhythm - April 28, 2022 Category: Cardiology Authors: Tahmeed Contractor, Rahul Bhardwaj, Ravi Mandapati, Kamal Kotak, Jalaj Garg Tags: Research Letter Source Type: research

Incidence of new-onset atrial fibrillation after transcatheter patent foramen ovale closure using 15 years of Ontario administrative health data
Individuals with patent foramen ovale (PFO) routinely undergo transcatheter closure (TC) for secondary prevention of recurrent stroke. However, some evidence suggests that TC may increase the risk of new-onset atrial fibrillation (AF).
Source: Heart Rhythm - April 13, 2022 Category: Cardiology Authors: Laura Oliva, Ella Huszti, Ruth Hall, Lusine Abrahamyan, Eric Horlick Source Type: research

Incidence of new onset atrial fibrillation after transcatheter pfo closure using 15 years of ontario administrative health data
Individuals with patent foramen ovale (PFO) routinely undergo transcatheter closure (TC) for secondary prevention of recurrent stroke. However, there has been some evidence suggesting that TC may increase the risk of new-onset atrial fibrillation (AF).
Source: Heart Rhythm - April 13, 2022 Category: Cardiology Authors: Laura Oliva, Ella Huszti, Ruth Hall, Lusine Abrahamyan, Eric Horlick Source Type: research

The impact of heart rate circadian rhythm on in-hospital mortality in stroke and critically ill patients: insights from the eICU Collaborative Research Database
Data showing the impact of dysregulated heart rate circadian rhythm in stroke and critically ill patients are scarce.
Source: Heart Rhythm - March 30, 2022 Category: Cardiology Authors: Zhengning Yang, Zhe Li, Xu He, Zhen Yao, Xiaoxia Xie, Sha Zhang, Yan Shen, Shaowei Li, Shuzhen Qiao, Zhenliang Hui, Chao Gao, Jun Chen Source Type: research

The impact of heart rate circadian rhythm on in-hospital mortality in patients with stroke and critically ill: Insights from the eICU Collaborative Research Database
Data showing the impact of dysregulated heart rate circadian rhythm in patients with stroke and critically ill are scarce.
Source: Heart Rhythm - March 30, 2022 Category: Cardiology Authors: Zhengning Yang, Zhe Li, Xu He, Zhen Yao, Xiaoxia Xie, Sha Zhang, Yan Shen, Shaowei Li, Shuzhen Qiao, Zhenliang Hui, Chao Gao, Jun Chen Source Type: research

EP News: Allied Professionals
In this non-prespecified, post hoc analysis of the AUGUSTUS (The Open-Label, 2 x 2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention) trial (Harskamp et al. J Am Coll Cardiol. 2022;79:417-27. PMID-35115097), the authors sought to evaluate whether the risk of bleeding or stroke as assessed by baseline HAS-BLED and CHA2DS2-VASc scores affected the results of the trial.
Source: Heart Rhythm - March 9, 2022 Category: Cardiology Authors: Erica S. Zado Source Type: research

Procedural and Short-Term Follow-Up Outcomes of Amplatzer Amulet Occluder versus Watchman FLX Device: A Meta-Analysis
Left atrial appendage (LAA) occlusion provides effective protection against thromboembolic (TE) events in high-risk atrial fibrillation patients. Two percutaneous devices are currently available in the United States for stroke prophylaxis: the WatchmanTM device (Boston Scientific, USA) and the AmplatzerTM AmuletTM Left Atrial Appendage Occluder (Abbott, USA). The latter has recently received Food and Drug Administration approval as a result of the findings of the Amulet IDE randomized trial (1), which showed superiority for LAA occlusion (lower rates of leaks>5mm) based on a comparison between the second generation Amplatz...
Source: Heart Rhythm - February 11, 2022 Category: Cardiology Authors: Domenico G. Della Rocca, Michele Magnocavallo, Carola Gianni, Sanghamitra Mohanty, Veronica N. Natale, Amin Al-Ahmad, Carlo Lavalle, Rodney P. Horton, Luigi Di Biase, Andrea Natale Source Type: research

EP News Clinical February 2022
Temporal Association Between Episodes of Atrial Fibrillation and Risk of Ischemic Stroke
Source: Heart Rhythm - February 2, 2022 Category: Cardiology Authors: N. A. Mark Estes Source Type: research

EP News: Clinical
Singer et  al (JAMA Cardiol 2021;6:1364, PMID 34586356) evaluated the temporal association between episodes of atrial fibrillation (AF) and stroke in patients with cardiac implantable electronic devices (CIEDs). In a case-crossover study, data from an electronic health record database were linked with record s of patients with CIEDs. The prespecified duration of AF was ≥5.5 hours during days 1–30 vs days 91–120 prestroke. The main outcome was odds ratio (OR) for stroke comparing AF during days 1–30 vs days 91–120 prestroke.
Source: Heart Rhythm - February 2, 2022 Category: Cardiology Authors: N.A. Mark Estes Tags: EP NEWS Source Type: research

Unequal prescription of anticoagulants among females and males with atrial fibrillation and similar stroke risk – should we omit sex category from the CHA2DS2-VASc score?
The CHA2DS2-VASc stroke risk score has been recommended by the European Society of Cardiology atrial fibrillation (AF) guidelines to guide decision on oral anticoagulation (OAC) prescription in AF patients. Whereas female sex was initially considered an individual risk factor warranting antithrombotic treatment in all female AF patients independent of other risk factors, this recommendation was revised as growing evidence showed that female sex is rather a risk modifier as sex does not contribute to stroke risk in the absence of other risk factors.
Source: Heart Rhythm - January 12, 2022 Category: Cardiology Authors: Jaap Seelig, Gordon Chu, Emmy M. Trinks-Roerdink, Ron Pisters, Tim AC. de Vries, Hugo ten Cate, Geert-Jan Geersing, Frans H. Rutten, Menno V. Huisman, Martin EW. Hemels Source Type: research

EP News: Clinical
Lakkireddy et  al (Circulation 2021;144:1543, PMID 34459659) evaluated the safety and effectiveness of the Amulet left atrial appendage occluder (A) compared with the Watchman device (W). Patients with nonvalvular atrial fibrillation at an increased risk of stroke were randomly assigned (1:1) to A or W. The prim ary end points included safety (composite of procedure-related complications, death, or major bleeding at 12 months) and effectiveness (composite of ischemic stroke or systemic embolism at 18 months).
Source: Heart Rhythm - December 7, 2021 Category: Cardiology Authors: N.A. Mark Estes Tags: EP News Source Type: research

New frontiers for improving outcomes after transcatheter aortic valve implantation: the role of the conduction system and the impact of pacemakers
Transcatheter aortic valve implantation (TAVI) is at least as safe and effective as surgical aortic valve replacement (SAVR) in patients with severe symptomatic aortic stenosis for the endpoints of all-cause mortality, stroke and heart failure hospitalizations across the spectrum of surgical risk1,2. Despite iterative advances in technology and refinements in procedural technique, conduction disturbances are not infrequent and occur more commonly after TAVI than after surgery. In the most recent low-risk randomized trials2,3 comparing TAVI to SAVR, the rates of permanent pacemaker implantation (PPI) were 6.6% with the ball...
Source: Heart Rhythm - August 18, 2021 Category: Cardiology Authors: Yousif Ahmad, Raj Makkar Source Type: research

EP News: Clinical
Rillig et  al (Circulation July 30, 2021; https://doi.org/10.1161/CIRCULATIONAHA.121.056323, PMID: pending) assessed the effect of early rhythm control (ERC) therapy (using antiarrhythmic drugs or catheter ablation) compared to usual care (UC; allowing rhythm control therapy to improve symptoms) on outcomes in prespecified patients with heart failure in the EAST-AFNET 4 trial. During 5.1-year follow-up, the composite primary outcome of cardiovascular death, stroke, or hospitalization for worsening of heart failure or for acute coronary syndrome occurred less often in patients randomized to ERC therapy (94/396; 5.7 per 100...
Source: Heart Rhythm - August 8, 2021 Category: Cardiology Authors: N.A. Mark Estes Tags: EP News Source Type: research

B-po03-108 combined minimally invasive approach to left atrial ablation (convergent procedure) with left atrial appendage clip for persistent atrial fibrillation
Atrial fibrillation (AF) is a major cause of structural heart disease, stroke, with increased hospitalizations. Patients can require multiple procedures and anti-arrhythmics to maintain sinus rhythm (SR). Patients with AF refractory to pharmacological and catheter ablations can be offered the Convergent Procedure. Traditional endocardial ablation is combined with a staged epicardial ablation via a subxiyphoid direct approach for radiofrequency lesion placement on the posterior left atrial wall. The left atrial appendage (LAA) occlusion is achieved with clip application (AtriClip LAA exclusion system, AtriCure, Mason, OH, USA).
Source: Heart Rhythm - July 28, 2021 Category: Cardiology Authors: Kathryn Mulryan, Stephen Frohlich, Fiona Kehoe, Jonathan C. Lyne, Karen C. Redmond Source Type: research